Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

CONCLUSIONS: Adequately dosed subcutaneous racemic ketamine was efficacious and safe in treating TRD over a 4-week treatment period. The subcutaneous route is practical and feasible.PMID:38108319 | DOI:10.1192/bjp.2023.79

Source: The British Journal of Psychiatry for Mental Science - December 18, 2023 Category: Psychiatry Authors: Colleen Loo Nick Glozier David Barton Bernhard T Baune Natalie T Mills Paul Fitzgerald Paul Glue Shanthi Sarma Veronica Galvez-Ortiz Dusan Hadzi-Pavlovic Angelo Alonzo Vanessa Dong Donel Martin Stevan Nikolin Philip B Mitchell Michael Berk Gregory Carter Source Type: research